Biotechnology : Highlights
: Biotechnology Articles
Editorial: Wrong numbers?With biotech infiltrating multiple industries and fewer life science ventures listing on stock exchanges, what do we really learn from surveying the set of public biotech companies? Nature Biotechnology, vol. 28 #8, pp761-761 |
Editorial: MAQC-II: analyze that!The MAQC consortium's latest study suggests that human error in handling DNA microarray data analysis software could delay the technology's wider adoption in the clinic. Nature Biotechnology, vol. 28 #8, pp761-761 |
News and Views: Can HIV be cured with stem cell therapy?Transplantation of human hematopoietic stem cells engineered to lack the viral coreceptor CCR5 confers resistance to HIV infection in mice. Nature Biotechnology, vol. 28 #8, pp807-810 |
News and Views: Microarrays in the clinicThe MicroArray Quality Control (MAQC) consortium has evaluated methods for making clinically useful predictions from large-scale gene expression data. Nature Biotechnology, vol. 28 #8, pp810-812 |
News and Views: Shaking up genome engineeringA new method generates genome-scale modified bacteria with unprecedented ease. Nature Biotechnology, vol. 28 #8, pp812-813 |
News and Views: The expanding family of dendritic cell subsetsThe recent identification of human CD141+ dendritic cells as a counterpart of mouse CD8+ dendritic cells may be useful in developing vaccines and immunotherapies. Nature Biotechnology, vol. 28 #8, pp813-815 |
Research: The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsThe Microarray Quality Control consortium pitted 36 teams against each other to evaluate methods for creating genomic classifiers, computational tools for interpreting gene expression profiles. The performance of the classifiers on blinded validation data?and metadata on the analytic methods?reveal the challenges facing the field. Nature Biotechnology, vol. 28 #8, pp827-838 |
Research: Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivoHolt et al. describe an anti-HIV strategy in which human hematopoietic stem/progenitor cells are modified with zinc-finger nucleases to knock out the viral co-receptor CCR5. Transplantation of these cells into mice confers resistance to HIV, as shown by higher human T-cell counts and lower viral loads compared with animals that received unmodified cells. Nature Biotechnology, vol. 28 #8, pp839-847 |
Research: Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cellsPolo et al. show that early-passage induced pluripotent stem cells retain an epigenetic memory of their cell type of origin. These epigenetic differences affect the cells? differentiation potential and might be exploited to generate particular cell types of interest. Nature Biotechnology, vol. 28 #8, pp848-855 |
Research: Rapid profiling of a microbial genome using mixtures of barcoded oligonucleotidesTo identify genes affecting traits of interest in E. coli, Warner et al. describe a method to rapidly create and assay rationally mutated versions of every gene. The approach is applied to several traits, including tolerance to cellulosic hydrolysate, a biofuel precursor. Nature Biotechnology, vol. 28 #8, pp856-862 |
Research: Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteinsRecombinant glycoproteins produced in animal cell lines often bear the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). Ghaderi et al. show that two monoclonal antibodies in clinical use differ with respect to addition of Neu5Gc and propose that drug developers should consider the consequences of the Neu5Gc modification. Nature Biotechnology, vol. 28 #8, pp863-867 |
Research: Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profilingEfforts to study ubiquitination have been hampered by the large size of ubiquitin relative to other post-translational modifications. Xu et al. use a monoclonal antibody specific for the adduct left after proteolysis of ubiquitinated proteins to analyze the differential regulation of ubiquitination at distinct sites within the same proteins. Nature Biotechnology, vol. 28 #8, pp868-873 |
